Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

UNICEF: J8 Meets G8
Fourteen young people from countries attending the G8 called on their respective leaders to get tough with countries who don"t meet climate change targets and teachers whose standards slip.
generic viagra online
Breastfeeding Can Save 1.3M Children Annually, WHO Says To Mark World Breastfeeding Week
About 1.3 million children"s lives could be saved each year by teaching new mothers how to breastfeed, but many women do not receive help and stop trying, the WHO said on Friday ahead of the start of World Breastfeeding Week, which runs from August 1 through August 7, Reuters reports. "Less than 40 percent of mothers worldwide breastfeed their infants exclusively in the first six months, as recommended by the WHO," the news service writes. Constanza Vallenas, a WHO medical officer in the Department of Child and Adolescent Health and Development, said women "don"t have the practical support" to help them get their infants to latch on properly and find a technique that prevents pain and discomfort. Vallenas said the problem exists in both rich and poor countries, and she called for "more assistance in hospitals, health clinics and communities for new mothers who need information and help," according to Reuters (MacInnis, 7/31).
News of the day
Hair Loss Is Not Inevitable For Increasing Numbers Of Chemo Patients
A grant from breast cancer charity, Walk the Walk, worth approximately ÷£250,000, has seen the delivery and installation of 21 scalp cooling machines into St James"s Institute of Oncology, Leeds. These ground breaking machines can reduce or even prevent hair loss in patients undergoing chemotherapy.
Endocrinology

Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment

Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec"s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead"s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead "said the new combination pill, along with Gilead"s experimental "quad" pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla," Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009